Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
Science Signaling|September 10, 2015
Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts with RNAiBenjamin E Housden, Alexander J Valvezan, Colleen Kelley, et al.Cell Reports|August 31, 2022
DEPDC5-dependent mTORC1 signaling mechanisms are critical for the anti-seizure effects of acute fastingChristopher J Yuskaitis, Jinita B Modasia, Sandra Schrötter, et al.The Journal of Biological Chemistry|January 17, 2019
Bile acid analogues are activators of pyrin inflammasomeIrina Alimov, Suchithra Menon, Nadire Cochran, et al.Iscience|November 17, 2022
Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complexMolly C McNamara, Aaron M Hosios, Margaret E Torrence, et al.Cancer Cell|October 24, 2017
mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic VulnerabilityAlexander J Valvezan, Marc Turner, Amine Belaid, et al.Nature|December 6, 2016
Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegansCaroline Heintz, Thomas Koed Doktor, Anne Lanjuin, et al.Nature|July 13, 2017
Corrigendum: Splicing factor 1 modulates dietary restriction and TORC1 pathway longevity in C. elegansCaroline Heintz, Thomas K Doktor, Anne Lanjuin, et al.Pediatric Neurology|June 9, 2016
Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning ConferenceMustafa Sahin, Elizabeth P Henske, Brendan D Manning, et al.Elife|February 20, 2016
Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activationAnthony J Covarrubias, Halil Ibrahim Aksoylar, Jiujiu Yu, et al.Cancer Cell|September 13, 2011
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumorsThomas De Raedt, Zandra Walton, Jessica L Yecies, et al.Pageof 12